Sarepta Therapeutics (SRPT +6.5%) moves up after the FDA granted Fast Track approval status for...


Sarepta Therapeutics (SRPT +6.5%) moves up after the FDA granted Fast Track approval status for it's lead drug candidates, AVI-7288 and AVI-7537, for Ebola and Marburg viruses respectively. Both drugs are being developed under a U.S. Department of Defense contract. AVI-7288 will start an upcoming Phase I multiple ascending dose study, however, development of AVI-7537 remains under a temporary stop-work order due to funding constraints.

From other sites
Comments (1)
  • largrasr
    , contributor
    Comments (4) | Send Message
     
    Makes their product offering more than a one pony show; should attract serious buy-out interest
    18 Sep 2012, 05:04 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs